Renaud L, Chaillol I, Galtier J, Bommier C, Tessoulin B, de Colella JMS, Lamy T, Borel C, Stamatoullas A, Gac AC, Morschhauser F, Andre M, Ghesquieres H, Traverse-Glehen A, Casasnovas O, Gastine T. Brentuximab vedotin as consolidation treatment in patients with stage I/II Hodgkin’s lymphoma and FDG-PET positivity after 2 cycles of ABVD: final analysis of the BRAPP2 trial. haematol [Internet]. 2020Sep.10 [cited 2026Aug.15];. Available from: https://haematologica.org/article/view/14343